Genome-wide association studies (GWAS) are increasingly utilized for identifying novel susceptible genetic variants for complex traits, but there is little consensus on analysis methods for such data. Most commonly used methods include single SNP analysis or haplotype analysis with Bonferroni correction for multiple comparisons. Since the SNPs in typical GWAS are often in linkage disequilibrium (LD), at least locally, Bonferonni correction of multiple comparisons often leads to conservative error control and therefore lower statistical power. In this paper, we propose a hidden Markov random field model (HMRF) for GWAS analysis based on a weighted LD graph built from the prior LD information among the SNPs and an efficient iterative conditional mode algorithm for estimating the model parameters. This model effectively utilizes the LD information in calculating the posterior probability that a SNP is associated with the disease. These posterior probabilities can then be used to define a false discovery controlling procedure in order to select the disease-associated SNPs. Simulation studies demonstrated the potential gain in power over single SNP analysis. The proposed method is especially effective in identifying SNPs with borderline significance at the single-marker level that nonetheless are in high LD with significant SNPs. In addition, by simultaneously considering the SNPs in LD, the proposed method can also help to reduce the number of false identifications of disease-associated SNPs. We demonstrate the application of the proposed HMRF model using data from a case-control genome-wide association study of neuroblastoma and identify one new SNP that is potentially associated with neuroblastoma.
Introduction
Genome-wide association studies (GWAS) are increasingly utilized for identifying novel susceptible genetic variants for complex traits, but there is little consensus on optimal study design and analysis. GWAS are designed to scan the entire genome for the identification of genetic variations associated with phenotypic traits, such as a disease condition, blood pressure, or body mass index. These studies usually examine several hundred thousand single nucleotide polymorphisms (SNPs) that explain most of the genetic variation across the genome as well as SNPs in a large array of candidate gene regions. Most GWAS involve some form of multistage design, which includes an initial scan of hundreds of thousands of SNPs on a sample of cases and controls, followed by testing a subset of the most promising markers on independent samples. Additional markers may also be included at later stages to better characterize the full spectrum of genetic variation in the targeted regions. GWAS have been demonstrated to be a powerful approach for the detection of genetic variants related to complex traits, such as age-related macular degenerative diseases (Klein et al., 2005) , prostate and breast cancers (Hunter et al., 2007) , and type 2 diabetes (Scott et al., 2007) . The Welcome Trust Case-Control Consortium has recently published a GWAS of seven diseases using 14, 000 cases and 3000 shared controls (Nature, 2007) . The success of these studies has provided solid evidence that GWAS represent a powerful approach to the identification of genes involved in common human diseases.
To date, the analytical methods of GWAS have largely been limited to the single SNP or SNP-SNP pair analysis, coupled with statistical techniques such as the Bonferroni procedure for controlling multiple comparisons. However, since SNPs in typical GWAS are in LD locally, simple Bonferonni correction can potentially be conservative and therefore lead to a loss of statistical power. In addition, if multiple SNPs are all in LD with the true disease variants, effectively utilizing the information from multiple SNPs in LD can potentially increase the power of detecting the SNPs associated with the disease. Local LD information has been mainly utilized in haplotype analysis based on sliding windows (Huang et al., 2007) .
However, such haplotype analysis may lead to loss of power due to high degrees of freedom.
In addition, it is often arbitrary to decide how many SNPs to consider in typical haplotype analysis. Browning and Browning (2007) developed an efficient multilocus association test for whole genome association studies using localized haplotype clustering, effectively using the local LD information, and demonstrated its application to the Wellcome Trust CaseControl Consortium data (Browning and Browning, 2008) . Eskin (2008) proposed a data-adaptive multiple comparison procedure to incorporate prior information of LD structure and molecular function in GWAS in order to increase power.
In this paper, we propose to formally incorporate LD information among the SNPs derived from the dataset itself or from the HapMap data (Altshuler et al., 2005) into identifying the disease-associated SNPs. In particular, we will first build a weighted LD graph based on pairwise LD measures among the SNPs. Such measures can either be derived from the HapMap project (Altshuler et al., 2005) or from the dataset itself. We then propose a hidden Markov random field model on such an LD graph in order to compute the posterior probability that a SNP is associated with the disease. The key is that the posterior probability that a given SNP is associated with disease depends not only on the genotype data observed at this SNP, but also on the genotypes of the SNPs that are in strong LD with this particular SNP. In addition, we propose a simple empirical Bayes method to borrow information across all the markers in estimating the model parameters. We provide an efficient iterative conditional mode (ICM) algorithm (Besag, 1986) to estimate the parameters and Gibbs sampling approach for estimating the posterior probabilities. These posterior probabilities can be used to define a false discovery rate (FDR) controlling procedure in order to select the relevant SNPs.
Different from the standard FDR control procedure of Benjamini and Hochberg (1995) , this posterior probability-based FDR control accounts for SNP dependency explicitly and is expected to gain power in detecting the disease-associated SNPs. The proposed HMRF model for accounting for the LD dependency of the SNPs is somewhat similar to some recently developed HMRF models for the analysis of microarray gene expression data in order to account for known regulatory network information (Wei and Li, 2007; Wei and Li, 2008; Wei and Pan, 2007) .
The rest of the paper is organized as follows: in Methods, we present our proposed HMRF model for SNPs data and the ICM algorithm for estimating the parameters. We also present a Gibbs sampling approach to estimate the posterior probabilities and use these probabilities to define the false discovery rate. In Results, we present results from the analysis of a casecontrol neuroblastoma dataset and simulation results to demonstrate the methods and to compare the power with single-marker analysis. Finally, we present a brief summary and discussion of our methods and results. SNPs are greater than τ , we expect that X s and X s are dependent. We propose to model such dependency using a simple discrete Markov random field model (Besag, 1974; Besag, 1986 ) with the following joint probability function for
where γ and β ≥ 0 are the two model parameters, and β measures dependencies of X s for SNPs in LD. In this model, the parameter β > 0 encourages the SNPs that are in LD to
have similar values of X s . We assume that the true association state X is a realization of a locally dependent discrete MRF with a specified distribution {p(X)}. This is in contrast to the hidden Markov model where some time or spatial order of the SNPs has to be assumed.
The conditional association state for SNP s, given the states of all neighboring SNPs is
where N s represents the neighbors of the SNP s on the LD graph.
An empirical Bayes model for genotype data
In order to relate the latent vector X to the observed genotypes, we further assume that given any particular realization of X, the random variables Y = (Y 1 , ..., Y p ) are conditionally independent with the following conditional density,
where P (Y s |X s ) is the joint probability of the observed genotypes over m + n individuals at the SNP s given the latent state X s .
In order to specify f (Y s |X s ), let θ s = (θ s1 , θ s2 , θ s3 ) be the genotype frequencies at the sth SNP in the case population, and ρ s = (ρ s1 , ρ s2 , ρ s3 ) be the genotype frequencies at the sth SNP in the control population, for genotype values of 0, 1 and 2, respectively. We assume that both of these frequencies across all the SNPs have a Dirichlet prior with parameter 
On the other hand, if SNP s is associated with the disease, i.e., when X s = 1, cases and controls should have different genotype frequencies, in which case we have
Together the probability models (1), (3) and (4) define a hidden Markov random field model, where X is the vector of the hidden states that follows a discrete Markov random field (1) and (3) and (4) define the emission probabilities.
Parameter estimation using the ICM algorithm and a FDR controlling procedure
In order to estimate the model parameters Φ = (γ, β) in the MRF model and α = (α 1 , α 2 , α 3 )
in the emission probabilities, we propose to use the following ICM algorithm, which was originally proposed by Besag (1986) for statistical image analysis. The algorithm involves iterative updates of model parameters and latent states and has the following steps:
1. Obtain an initial estimateX based on the single marker trend test using a p-value of 0.0001.
2.
Estimate α with the value ofα by maximizing the probability of the observed data given by equation (2), l(Y |X).
3. Estimate Φ with the value ofφ by maximizing the following pseudo-likelihood function,
The reason for using the pseudo-likelihood function here is that it is computationally difficult to compute the full likelihood function due to an unknown normalizing constant in the MRF model (1).
4.
Carry out a single cycle of ICM based on the currentX,α andφ, to obtain a newX.
Specifically, for s = 1 to p, update X s based on
5. Go to step 2 until max θ∈(α,Φ)
After the convergence of the algorithm, we propose to sample the latent vector X M times using Gibbs sampling based on the conditional probability (5). Based on these samples, we can estimate the posterior probability of q s = P r(X s = 0|Y Based on these posterior probabilities, let k = max{t :
This posterior probability-based definition of FDR has been widely used in the analysis of microarray gene expression data (Newton et al., 2001) and has been shown to control the FDR at the appropriate level α and to obtain optimal false non-discovery rates in the setting of hidden Markov models (Sun and Cai, 2008) .
Note that if we fix β = 0 in the MRF model (1), i.e., if we do not consider the LD dependency of the SNPs, the procedure reduces to a simple empirical Bayes (EB) procedure for the analysis of genetic association data in order to borrow information across all the SNPs.
Results

Application to a Neuroblastoma Case-Control Data Set
Neuroblastoma (NB) is a common and lethal pediatric malignancy, but despite significant effort the genetic events that initiate tumorigenesis were until recently unknown (Mosse et al., 2008) . We had hypothesized that NB is a complex disease that results from the interaction of mutant alleles with relatively low to moderate effect on tumor initiation. To identify these genetic variants, Maris et al. (2008) reported a GWAS of NB where 1032 neuroblastoma cases and 2043 controls of European descent were genotyped using the Illumina 550K SNP chips and they observed a significant association between NB and the common minor alleles of three consecutive SNPs at chromosome band 6p22 and containing the predicted genes ; allelic odds ratio, 1.39 to 1.40) using single SNP trend tests. Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of NB development (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
To demonstrate our proposed HMRF modeling approach, we reanalyzed the 30,216 SNPs on chromosome 6 that passed the standard quality controls (see Maris et al. 2008 for details). We grouped these SNPs into groups of 1000 SNPs along the genome and fitted our proposed HMRF for each of these groups in order to facilitate the computation. We ran 10,000 Gibbs samples to obtain the posterior probability of a SNP being associated with the Figure 2 shows the results from both single SNP analysis based on the chi-square tests and our proposed HMRF model. We observed that many SNPs have almost zero estimated probability of being associated with NB. We show in Table 1 Table 1 ).
Simulation Studies
To demonstrate the proposed methods, we conducted a simulation study. In order to obtain more realistic LD patterns among the SNPs, our simulation was based on sampling from the 3075 individuals in the case-control study of neuroblastoma analyzed in the previous section.
Particularly, we consider a region of 998 SNPs around the chromosome band 6p22 and select 20 SNPs as the true SNPs with relative risk of -1.5 for 10 such SNPs and 2.0 for another 10
SNPs. These disease-associated SNPs have 6 to 9 neighboring SNPs with r 2 ≥ 0.4. Figure   1 shows the constructed LD graph for 857 SNPs with at least one neighbor based on the data from 3075 samples from the NB GWAS study. Based on the true genotypes of these 3075 individuals, we simulated the disease probability using the following logistic regression model to give a disease rate of 0.10,
, where β 0 = −4.2, β k = − log(1.5) for k = 1, · · · , 10 and β k = log(2.0) for k = 11, · · · , 20.
Based on this model, we repeatedly generated the disease status for the 3075 individuals until we obtained 1000 cases and 1000 controls. The 20 true disease variants were then removed from our analysis. In order to assess the performance of selecting the relevant SNPs, the 117 SNPs that are in LD with the true variants with r 
Discussion
Since many SNPs in GWAS are in LD, it is important to efficiently utilize such LD information in order to increase the power of detecting disease-associated SNPs. In this paper, we introduce a hidden Markov random field model to account for LD in analysis of the SNP data from GWAS, where the pair-wise LD measurements are used to define a weighted LD graph and a Markov random field model based on the constructed LD graph is used to model the dependency among the SNPs. In addition, a simple empirical Bayes model is proposed in order to borrow information across all the SNPs. Our simulation indicates that the proposed method can lead to an increase in sensitivity in identifying the SNPs that are associated with the disease. We used the GWAS of neuroblastoma to demonstrate the computational feasibility of the methods and the advantage that one can gain over the simple commonly used single SNP analysis. The proposed method is especially effective in identifying the SNPs with borderline significance at the single-marker level that nonetheless are in high LD with significant SNPs, as demonstrated by our analysis of the neuroblastoma dataset. In addition, by simultaneously considering the SNPs in LD, the proposed method can also help to reduce the number of false identifications of disease-associated SNPs.
Although Bonferonni correction has been widely applied in GWAS, analytical and simulation studies by Sabatti et al. (2003) have shown the the FDR procedure of Benjamini and Hochberg (1995) can effectively control the FDR for the dependent tests encountered in case-control association studies and increase power over more traditional methods. However, the direct application of the FDR procedure can lead to loss of power due to the dependency among tests, although the FDR can still be controlled (Benjamini and Yekutieli, 2001 ). The most effective way of correcting this problem relies on developing a precise model for the dependency among the SNPs and incorporating it in the definition of a FDR controlling procedure (Sabatti et al., 2003) . The HMRF model proposed provides one such model and we expect some gain in power over the standard FDR controlling procedure ignoring the dependency. For the hidden Markov model, Sun and Cai (2008) proved the optimal power of a posterior probability-based FDR procedure while controlling the FDR. It is easy to show that if the model we used is the true model and the true parameters are known, our proposed posterior probability-based FDR controlling procedure can indeed control the FDR with a minimal false non-discovery rate and therefore the optimal power. However, it is not clear that such a result holds when the parameters are estimated using the ICM algorithm. This deserves further investigation.
The method in this paper was developed for case-control GWAS data; however, it can be easily extended to continuous quantitative traits where one only needs to redefine the emission probabilities. One such probability can be based on the empirical Bayes linear models as in the Limma method for microarray gene expression data analysis (Smyth, 2004; Li et al., 2008) . The method in this paper can also be extended to incorporate the prior genetic network such as the protein-protein interaction network information into the analysis of GWAS data, where one can create a weighted LD graph for the SNPs within a given gene. The LD-graphs are then linked based on the a priori gene or protein-protein interaction network to form a large SNP-network. A HMRF model can then be defined on this combined network that can help to identify the subnetworks of SNPs that might be related to disease risk. This network-based analysis of genomic data has shown some promise in the analysis of microarray gene expression data (Wei and Li, 2007; Wei and Li, 2008; Wei and Pan, 2007) .
We would also expect some potential gain in sensitivity in identifying the disease-associated genetic variants in the analysis of GWAS data. It would be interesting to investigate more on how much one can gain in analysis of GWAS data when the prior biological information is effectively utilized in the analysis. 
